antidepressants and breast and ovarian cancer risk a review of the literature and researchers financial associations with industry抗抑郁药和乳腺癌和卵巢癌风险文献的回顾和研究人员的金融和行业协会.pdf

Antidepressants and Breast and Ovarian Cancer Risk: A Review of the Literature and Researchers’ Financial Associations with Industry 1,3 2 3,4 5 6 Lisa Cosgrove *, Ling Shi , David E. Creasey , Maria Anaya-McKivergan , Jessica A. Myers , Krista F. Huybrechts6 1The Edmond J. Safra Center for Ethics, Harvard University, Cambridge, Massachusetts, United States of America, 2 Department of Nursing and Health Sciences, University of Massachusetts, Boston, Massachusetts, United States of America, 3 Department of Counseling and School Psychology, University of Massachusetts, Boston, Massachusetts, United States of America, 4 Department of Psychiatry, Harvard Medical School, Boston, Massachusetts, United States of America, 5 College of Social Sciences, University of Phoenix, Yuma, Arizona, United States of America, 6 Division of Pharmacoepiodemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, United States of America Abstract Background: Antidepressant (AD) use has been purported to increase the risk of breast and ovarian cancer, although both epidemiological and pre-clinical studies have reported mixed results [1–6]. Previous studies in a variety of biomedical fields have found that financial ties to drug companies are associated with favorable study conclusions [7]. Methods and Findings: We searched English-language articles in MEDLINE, PsychINFO, the Science Citations Index and the Cochrane Central Register of Controlled Clinical Trials (through November 2010). A total of 61 articles that assessed the relationship between breast and ovarian cancer and AD use and articles that examined the effect of ADs on cell growth